By Christy Santhosh Sept 11 (Reuters) - AstraZeneca's breast cancer pill failed to meet the main goal of improving progression-free survival in a late-stage trial, the company said on Friday, a week ...
AstraZeneca’s Camizestrant failed the main goal in the SERENA-4 breast cancer trial The drug showed numerical but not statistically significant improvement in progression-free survival FDA recently ...
AstraZeneca’s breast cancer pill camizestrant (Etcamah) failed to improve progression-free survival in a late-stage trial when added to standard therapy, despite an earlier ESR1 mutation–targeted ...
The Etcamah results came a week after the U.S. granted approval for the drug for advanced breast cancer upon the detection of a specific mutation.
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
AstraZeneca's breast cancer drug Etcamah did not meet its main goal in a late-stage trial. The drug showed only a numerical improvement when combined with palbociclib. This marks a setback for the ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Sept 11 — AstraZeneca's breast cancer drug failed to meet the main goal of improving progression-free survival during a late-stage trial, it said on Friday, marking a setback for the recently ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results